Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Not Yet Opened 06-20 16:00:00 EDT

26.59

+0.63

+2.43%

盘后26.40

-0.19-0.71%

17:51 EDT

High26.65	Low25.20	Vol1.82M
Open25.81	D1 Closing25.96	Amplitude5.59%
Mkt Cap716.12M	Tradable Cap655.49M	Total Shares26.93M
T/O48.04M	T/O Rate7.38%	Tradable Shares24.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":26.59,"timestamp":1718913600000,"preClose":25.96,"halted":0,"volume":1819560,"hourTrading":{"tag":"盘后","latestPrice":26.4,"preClose":26.59,"latestTime":"17:51 EDT","volume":1204346,"amount":32023483.39,"timestamp":1718920304442},"delay":0,"floatShares":24651774,"shares":26931826,"eps":-4.023774,"marketStatus":"Not Yet Opened","change":0.63,"latestTime":"06-20 16:00:00 EDT","open":25.81,"high":26.65,"low":25.2,"amount":48044280.8904,"amplitude":0.055855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.023774,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1718956800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":25.96,"preHourTrading":{"tag":"盘前","latestPrice":26.61,"preClose":25.96,"latestTime":"09:25 EDT","volume":359,"amount":9460.790184000001,"timestamp":1718889926958},"postHourTrading":{"tag":"盘后","latestPrice":26.4,"preClose":26.59,"latestTime":"17:51 EDT","volume":1204346,"amount":32023483.39,"timestamp":1718920304442},"volumeRatio":2.891621,"impliedVol":0.7472,"impliedVolPercentile":0.3492},"requestUrl":"/m/hq/s/ARCT","defaultTab":"news","newsList":[{"id":"2444215474","title":"BRIEF-Arcturus Therapeutics Appoints Moncef Slaoui To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2444215474","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444215474?lang=en_us&edition=fundamental","pubTime":"2024-06-20 20:34","pubTimestamp":1718886855,"startTime":"0","endTime":"0","summary":"June 20 (Reuters) - Arcturus Therapeutics Holdings Inc :   * ARCTURUS THERAPEUTICS APPOINTS MONCEF SLAOUI, PH.D., TO BOARD OF DIRECTORSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4534","BK4139","BK4551","BK4588","LENZ","BK4585","BK4548","BK4533","MRNA","BK4568","ARCT","BK4532"],"gpt_icon":0},{"id":"2444152582","title":"Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2444152582","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444152582?lang=en_us&edition=fundamental","pubTime":"2024-06-20 20:00","pubTimestamp":1718884800,"startTime":"0","endTime":"0","summary":"Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH. SAN DIEGO, June 20, 2024----Arcturus Therapeutics Holdings Inc. , a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors.\"Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and commercialization of several therapeutics and vaccines,\" said Joseph Payne, President & Chief Executive Officer of Arcturus. \"We warmly welcome Moncef to the Board of Directors and look forward to working with him as we advance our pipeline of next generation mRNA medicines.\". Dr. Slaoui holds a Ph.D. in Molecular Biolog","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/moBaQMLu6S3NeIEqbk8GSg--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/6a98f9c8f33404a9b58feaa6db907291","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/moBaQMLu6S3NeIEqbk8GSg--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/6a98f9c8f33404a9b58feaa6db907291"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-appoints-moncef-slaoui-120000813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","RNA","BK4588","MRNA","GSK.UK","BK4007","GSK","LU1829250122.USD","BK4139","ARCT","LENZ","BK4585","BK4532"],"gpt_icon":0},{"id":"2443956840","title":"Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2443956840","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443956840?lang=en_us&edition=fundamental","pubTime":"2024-06-15 14:49","pubTimestamp":1718434170,"startTime":"0","endTime":"0","summary":"On June 12, 2024, Andy Sassine, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc , executed a significant transaction by selling 50,000 shares of the company. The sale was documented in an SEC Filing. Following this transaction, the insider now owns 220,526 shares of the company.GuruFocus has detected 5 Warning Signs with ARCT.Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines. The company's diverse pipeline includes candidates in preclinical and clinical stages targeting various medical conditions.Over the past year, the insider transaction history for Arcturus Therapeutics Holdings Inc shows a trend with 0 insider buys and 12 insider sells. Specifically, Andy Sassine has sold a total of 50,000 shares and has not purchased any shares in the same timeframe.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C.uHwN9rYgMFrdazI8hvOA--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/e332f4f6c214210afc9d8a0e072d458c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C.uHwN9rYgMFrdazI8hvOA--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/e332f4f6c214210afc9d8a0e072d458c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-sale-cfo-andy-sassine-064930570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2443985557","title":"Arcturus Therapeutics Endorses Plan Amendment and Re-elects Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2443985557","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443985557?lang=en_us&edition=fundamental","pubTime":"2024-06-15 05:19","pubTimestamp":1718399967,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) has shared an update. Arcturus Therapeutics Holdings Inc. stockholders convened for their annual meeting, endorsing a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arcturus-therapeutics-endorses-plan-amendment-and-re-elects-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arcturus-therapeutics-endorses-plan-amendment-and-re-elects-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ARCT"],"gpt_icon":0},{"id":"2441071893","title":"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Arcturus Therapeutics (ARCT) and Blueprint Medicines (BPMC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2441071893","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441071893?lang=en_us&edition=fundamental","pubTime":"2024-06-08 20:40","pubTimestamp":1717850440,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN – Research Report), ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-arcturus-therapeutics-arct-and-blueprint-medicines-bpmc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-arcturus-therapeutics-arct-and-blueprint-medicines-bpmc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","IE00B7SZLL34.SGD","ARCT","BK4137","BK4505","IE00B19Z3B42.SGD","HCSG","BK4139","BMRN","BPMC","IE0002270589.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2441509090","title":"Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble","url":"https://stock-news.laohu8.com/highlight/detail?id=2441509090","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441509090?lang=en_us&edition=fundamental","pubTime":"2024-06-08 03:16","pubTimestamp":1717787774,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis.Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled therapeutic generally was safe and well tolerated among the healthy patients participating in the early-stage trial as well as the four adult patients with cystic fibrosis.Lung function also improved in the cystic fibrosis patients after they received two doses of ARCT-032, the company said. It plans to complete phase 1b shortly.Price: 30.10, Change: -12.50, Percent Change: -29.34","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ARCT","BK4139"],"gpt_icon":1},{"id":"2441409729","title":"7 Actionable trading ideas - Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2441409729","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441409729?lang=en_us&edition=fundamental","pubTime":"2024-06-08 02:23","pubTimestamp":1717784606,"startTime":"0","endTime":"0","summary":"Piper Sandler analysts highlighted seven actionable stock ideas in a Technical Research note. They said that they see equities as “semi-charmed -- pleasant but with some problems.” The S&P 500 (SP500)","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832105060/image_832105060.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832105060/image_832105060.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4114231-7-actionable-trading-ideas-piper-sandler","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["03165","LU0053666078.USD","LU1196500208.SGD","LU1852331112.SGD","SG9999001440.SGD","LU0466842654.USD","LU2087621335.USD","BK4139","LU2326559502.SGD","LU0234570918.USD","LU2756315318.SGD","LU0056508442.USD","LU1221951046.USD","LU1861220033.SGD","JNJ","SMH","LU0348723411.USD","LU1221951129.SGD","LU1267930813.SGD","QQQE","BROS","LU1032955483.USD","LU1059921491.USD","LU1585245621.USD","LU2347655156.SGD","WEN","LU1861215975.USD","LU1935042991.SGD","LU1066053197.SGD","LU1032466523.USD","LU2133065610.SGD","ARCT","ASML","IE00BSNM7G36.USD","LU0640476718.USD","RSP","LU1839511570.USD","LU0234572021.USD","NWSA","LU2602419157.SGD","LU0316494557.USD","LU0820562030.AUD","IE00BWXC8680.SGD","LU1244550577.SGD","BK4592","LU0889566641.SGD","LU1430594728.SGD","LU1023059063.AUD","LU1720051108.HKD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2441500099","title":"Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2441500099","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441500099?lang=en_us&edition=fundamental","pubTime":"2024-06-08 00:46","pubTimestamp":1717778771,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic fibrosis. The stock rallied last week in reaction to early data from the study posted ahead of a presentation at the European Cystic Fibrosis Conference on Friday. The readout represented 36 study participants, including four adults with cystic fibrosis who received ARCT-032 as part of a Phase 1b trial. Following the event, based on eight-day interim data from the Phase 1b trial, Arcturus  said ARCT-032, on average, led to a nearly 6% relative change in FEV1 , a metric used to measure lung function in cystic fibrosis. The company noted that patients and healthy individuals in the early-stage trials didn’t develop severe adverse events linked to the drug. It added that ARCT-032, an inhaled messenger-RNA-based therapy, was generally safe and well tolerated.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325625958/image_1325625958.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325625958/image_1325625958.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4114201-arcturus-stock-falls-cystic-fibrosis-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","ARCT"],"gpt_icon":1},{"id":"2441006772","title":"Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2441006772","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441006772?lang=en_us&edition=fundamental","pubTime":"2024-06-07 22:30","pubTimestamp":1717770600,"startTime":"0","endTime":"0","summary":"ARCT-032 is safe and well tolerated with no serious adverse events  in 36 study participants, including 4 adults with cystic fibrosis . Phase 1b interim data includes a CF participant with Class 1 mutations and three participants with F508del mutations being treated with Trikafta. Early trend of improved lung function with an average absolute response of +4.0%  and relative change of +5.8% FEV1 on Day 8, after two doses of ARCT-032. Clinical data is consistent with pre-clinical CF ferret model data. SAN DIEGO, June 07, 2024----Arcturus Therapeutics Holdings Inc. , a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference in Glasgow, Scotland.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KCkfyFgKE3QMFwyt1tlYIQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/b315af0ab6dac78a60af40a961ae7469","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KCkfyFgKE3QMFwyt1tlYIQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/b315af0ab6dac78a60af40a961ae7469"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-presents-clinical-data-143000752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT","BK4139","BK4505","BK4585","RNA","CF","BK4588","LENZ","BK4093"],"gpt_icon":1},{"id":"2441629582","title":"Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2441629582","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441629582?lang=en_us&edition=fundamental","pubTime":"2024-06-05 07:00","pubTimestamp":1717542045,"startTime":"0","endTime":"0","summary":"Chief Scientific Officer & Chief Operating Officer Pad Chivukula of Arcturus Therapeutics Holdings Inc  sold 26,000 shares of the company on June 3, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 447,448 shares of the company.GuruFocus has detected 6 Warning Signs with ARCT.Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the development of novel RNA therapeutics for the treatment of various diseases. The company's proprietary technologies include lipid-mediated nucleic acid delivery systems and RNA constructs, which are used to develop therapies for diseases with high unmet medical need.Over the past year, Pad Chivukula has sold a total of 102,000 shares and has not purchased any shares. This recent sale is part of a broader trend observed within the company, where there have been 10 insider sells and no insider buys over the past year.According to the GF Value, the intrinsic value of the stock is estimated at $46.14,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VoTdlhjZ0G1xPoRq_OcxJw--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/bb957eea56b582ce5386ce1b8744365a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VoTdlhjZ0G1xPoRq_OcxJw--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/bb957eea56b582ce5386ce1b8744365a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-sale-chief-scientific-officer-230045210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COO","LU1992135472.HKD","LU2272731600.USD","GB00BDT5M118.USD","BK4588","BK4139","BK4198","LU1992135399.USD","LU2272731782.SGD","ARCT","BK4585"],"gpt_icon":1},{"id":"2439624018","title":"Vertex: Poised For Long-Term Growth Driven By Multiple Pipeline Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2439624018","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439624018?lang=en_us&edition=fundamental","pubTime":"2024-05-30 23:50","pubTimestamp":1717084235,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development.The company has outperformed Johnson & Johnson and the S&P 500 in terms of total ","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/180734981/image_180734981.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/180734981/image_180734981.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4696464-vertex-long-term-growth-driven-by-multiple-pipeline-catalysts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","ARCT","LU0251144936.SGD","LU1732800096.USD","LU0228659784.USD","IE0002270589.USD","IE00BFTCPJ56.SGD","LU0072462343.USD","LU0128522157.USD","BK4567","BK1517","LU0080751232.USD","BK1531","JNJ","BK1586","LU0163747925.USD","LU1506573853.SGD","IE00B5MMRT66.SGD","LU0320765992.SGD","LU1066051498.USD","LU0882574055.USD","BK1610","BK4588","LU0228367735.SGD","LU1430594728.SGD","LU1585245621.USD","VRTX","LU0315178854.USD","LU2347655156.SGD","LU0234570918.USD","LU0348805143.USD","LU0048597586.USD","MRNA","BK4138","LU0256863811.USD","IE0002141913.USD","LU0029874905.USD","LU1732799900.SGD","IE00B543WZ88.USD","VERX","LU0054450605.USD","BK4559","IE0009355771.USD","LU0234572021.USD","LU0792757196.USD","VTNR","80700","LU0640476718.USD","CF","00700"],"gpt_icon":0},{"id":"2439402505","title":"Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), Corcept Therapeutics (CORT) and Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2439402505","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439402505?lang=en_us&edition=fundamental","pubTime":"2024-05-29 19:26","pubTimestamp":1716981973,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Phreesia (PHR – Research Report), Corcept Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phreesia-phr-corcept-therapeutics-cort-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phreesia-phr-corcept-therapeutics-cort-and-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4139","CORT","BK4167","HCSG","BK4007","BK4137","PHR","ARCT"],"gpt_icon":0},{"id":"2439527116","title":"Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2439527116","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439527116?lang=en_us&edition=fundamental","pubTime":"2024-05-29 19:23","pubTimestamp":1716981803,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders are no doubt pleased to see that the share price has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arct/arcturus-therapeutics-holdings/news/arcturus-therapeutics-holdings-incs-nasdaqarct-share-price-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain",".IXIC","LU2210150020.SGD","QID","QQQ","BK4112","BK4588","NDAQ","QLD","TQQQ","BK4139","ARCT","LU2210149790.SGD","SQQQ","BK4585","PSQ","LU2095319765.USD","MNQmain"],"gpt_icon":0},{"id":"2439651034","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM), Arcturus Therapeutics (ARCT) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2439651034","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439651034?lang=en_us&edition=fundamental","pubTime":"2024-05-29 17:10","pubTimestamp":1716973825,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insmed (INSM – Research Report), Arcturus Therapeu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-insmed-insm-arcturus-therapeutics-arct-and-johnson-johnson-jnj?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-insmed-insm-arcturus-therapeutics-arct-and-johnson-johnson-jnj?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0882574055.USD","BK4534","LU1066051498.USD","LU1935042991.SGD","LU0795875169.SGD","BK4592","LU0792757196.USD","IE00B19Z3B42.SGD","BK4139","LU0122379950.USD","LU1074936037.SGD","SG9999002232.USD","LU2468319806.SGD","LU1244550221.USD","LU0114720955.EUR","BK4588","BK4559","LU1261432733.SGD","LU1057294990.SGD","LU1732799900.SGD","BK4533","LU1066053197.SGD","SG9999002224.SGD","LU1280957306.USD","IE00B1BXHZ80.USD","LU0889566641.SGD","IE0002270589.USD","HCSG","BK4137","LU0640476718.USD","BK4585","LU1196500208.SGD","BK4532","IE00B19Z3581.USD","LU1244550494.USD","LU1732800096.USD","LU1032466523.USD","INSM","LU1059921491.USD","LU1430594728.SGD","LU1506573853.SGD","BK4007","BK4568","LU1221951129.SGD","LU0466842654.USD","LU1221951046.USD","JNJ","ARCT","LU2602419157.SGD","BK4550"],"gpt_icon":0},{"id":"2438304955","title":"Arcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2438304955","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2438304955?lang=en_us&edition=fundamental","pubTime":"2024-05-28 23:55","pubTimestamp":1716911700,"startTime":"0","endTime":"0","summary":"Shares of Arcturus Therapeutics on Tuesday jumped after the company said it saw positive observations in the phase 1 study for its cystic fibrosis treatment candidate ARCT-032.The stock was up 23% to $37.40 in recent trading. Shares have risen 37% over the past 12 months.The late-stage clinical messenger RNA medicines and vaccines company said that the treatments for the first four patients were generally safe and well tolerated, without serious adverse events.\"Furthermore, we observed an encouraging trend towards lung function improvements in the first four cystic fibrosis participants after only two inhaled administrations,\" Chief Executive Joseph Payne said.Arcturus will present this new Phase 1b interim data at the June 7 European cystic fibrosis conference in Scotland.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ","BK4139"],"gpt_icon":0},{"id":"2438564324","title":"BRIEF-Arcturus Therapeutics Announces Positive Development For Cystic Fibrosis Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2438564324","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2438564324?lang=en_us&edition=fundamental","pubTime":"2024-05-28 19:00","pubTimestamp":1716894022,"startTime":"0","endTime":"0","summary":"May 28 (Reuters) - Arcturus Therapeutics Holdings Inc :   * ARCTURUS THERAPEUTICS ANNOUNCES POSITIVE DEVELOPMENT FOR CYSTIC FIBROSIS PROGRAMSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","ARCT"],"gpt_icon":0},{"id":"2438304322","title":"Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2438304322","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2438304322?lang=en_us&edition=fundamental","pubTime":"2024-05-28 18:30","pubTimestamp":1716892200,"startTime":"0","endTime":"0","summary":"Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024. First four CF patients demonstrated an average improvement of 4% FEV1 after two administrations. ARCT-032 has received Orphan Medicinal Product Designation from the European Medicines Agency  and Orphan Drug Designation from the U.S. Food and Drug Administration  to treat Cystic Fibrosis. ARCT-032 utilizes Arcturus' LUNAR lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. Expression of a functional copy of the CFTR mRNA in the lungs of people with CF has the potential to restore CFTR activity and mitigate the downstream effects that cause progressive lung disease. The ARCT-032 program is supported by preclinical data in rodents, ferrets and primates, as well as demonstrating re","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b_19NYvc0dzdqtc8UoYm_g--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/169b5feb30ea3795d532ea4a3d53373b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b_19NYvc0dzdqtc8UoYm_g--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/169b5feb30ea3795d532ea4a3d53373b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-announces-positive-development-103000438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4585","BK4139","LENZ","BK4505","RNA","ARCT"],"gpt_icon":0},{"id":"2437211045","title":"COVID-19 vaccine makers rebound amid post-pandemic prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2437211045","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437211045?lang=en_us&edition=fundamental","pubTime":"2024-05-23 02:00","pubTimestamp":1716400826,"startTime":"0","endTime":"0","summary":"Shares of Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Novavax (NASDAQ:NVAX) are continuing a recent upswing as investors look for their post-pandemic growth trajectory amid d","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253358164/image_1253358164.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253358164/image_1253358164.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4109471-covid-19-vaccine-makers-gain-post-pandemic-prospects","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00BBT3K403.USD","BK4139","PSQ","GSK","MNQmain","BK4539","ARCT","QID","SGXZ57979304.SGD","QLD","BK4548","LU0058720904.USD","LU0289739699.SGD","ADC","BK4501","BK4592","MRNA","IE00BLSP4452.SGD","IE00BLSP4239.USD","BK4532","BK4581","GSK.UK","LU0868494617.USD","LU0456855351.SGD","SG9999013999.USD","TQQQ","LU1057294990.SGD","BK4534","LU1023059063.AUD","VALN","BK4547","PFE","SG9999001176.USD","LU0122379950.USD","CVAC","LU0234572021.USD","SQQQ","BK4588","IE00B19Z3581.USD","LU1829250122.USD","QQQ",".IXIC","IE0002270589.USD","NQmain","SNY","XBI","NVAX","VXRT","BNTX","BK4080"],"gpt_icon":0},{"id":"2437291899","title":"Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2437291899","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437291899?lang=en_us&edition=fundamental","pubTime":"2024-05-22 22:26","pubTimestamp":1716387972,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4539","BK4139","ACHL","ARCT"],"gpt_icon":0},{"id":"2437263028","title":"Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2437263028","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437263028?lang=en_us&edition=fundamental","pubTime":"2024-05-22 11:00","pubTimestamp":1716346800,"startTime":"0","endTime":"0","summary":"Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durabl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/22/2886352/0/en/Achilles-Therapeutics-Announces-Research-Collaboration-with-Arcturus-Therapeutics-to-Explore-Second-Generation-Personalized-mRNA-Cancer-Vaccines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","LENZ","BK4585","BK4539","RNA","ARCT","ACHL","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":-0.1585},{"period":"1month","weight":-0.1092},{"period":"3month","weight":-0.2156},{"period":"6month","weight":-0.1612},{"period":"1year","weight":0.0632},{"period":"ytd","weight":-0.1567}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.0294},{"period":"3month","weight":0.0495},{"period":"6month","weight":0.1549},{"period":"1year","weight":0.2576},{"period":"ytd","weight":0.1508}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.080132},{"month":2,"riseRate":0.545455,"avgChangeRate":0.011691},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.021161},{"month":4,"riseRate":0.545455,"avgChangeRate":0.101832},{"month":5,"riseRate":0.636364,"avgChangeRate":0.1056},{"month":6,"riseRate":0.583333,"avgChangeRate":0.027884},{"month":7,"riseRate":0.636364,"avgChangeRate":0.122819},{"month":8,"riseRate":0.545455,"avgChangeRate":0.05911},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.078674},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.028789},{"month":11,"riseRate":0.636364,"avgChangeRate":0.065619},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.060891}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction